Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.
about
Clinical use of pharmacogenomic tests in 2009Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical UtilityFrom pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatmentComparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.Towards the clinical implementation of pharmacogenetics in bipolar disorder.Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop.Implementation and utilization of genetic testing in personalized medicine.Pharmacogenomics and personalized medicine in neuropsychiatry.Health system implications of direct-to-consumer personal genome testingClosing the gap between knowledge and clinical application: challenges for genomic translationDevelopment of determination of four analytes of Zhi-Shao-San decoction using LC-MS/MS and its application to comparative pharmacokinetics in normal and irritable bowel syndrome rat plasma.The promise and reality of pharmacogenetics in psychiatryPharmacogenomics of antidepressant treatment effectsNovel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.Information-seeking and sharing behavior following genomic testing for diabetes risk.Personalizing medicine with clinical pharmacogeneticsA formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.Why should genomic medicine become more evidence-based?Knowing me, knowing you.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Public health genomics approach to type 2 diabetes.The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.Regulatory agency consideration of pharmacogenomics.Implementing genomic medicine in the clinic: the future is here.Public health genomics: translating obesity genomics research into population health benefitsAbacavir hypersensitivity: a model system for pharmacogenetic test adoption.Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions.Implementation of CYP2D6 genotyping in psychiatry.Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.Outcomes of interest in evidence-based evaluations of genetic tests.Systematic review of psychosocial benefits and harms of genetic testing.Pharmacogenetic testing: time for clinical practice guidelines.Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism.Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.The EGAPP initiative: lessons learned.
P2860
Q24657536-070B0A39-A66F-4ED7-85D3-874999987428Q26775813-A3CB4064-9296-4B93-9097-826EA6D84672Q27015830-4C977428-0E2C-4246-805C-D663038E0F0EQ30416074-73258008-B778-4026-A646-9B332D585687Q33326612-9436682E-ED53-4BB6-B171-C2027CA9D664Q33688133-A52F54EA-1EE2-45FA-82FB-F2003A3F63D1Q33730306-D0E69A86-61D9-42C0-9289-7053A474696DQ34013022-75493515-35AA-4F27-9A64-BA16C5192356Q34113976-BA07554D-B3AD-453A-BBC2-69C5079963BEQ34147916-E6195E52-AEEA-4941-9BB3-F001BC6C25CDQ34280025-B09EE4D7-0D15-41F7-B83F-EF4A58CCAF01Q34515586-56669CE9-70C6-4D3B-99EF-BC468B45EEA1Q35126221-D0B1F902-682E-4D42-A79D-06F3B52E201CQ35136319-2D9F2769-5DB4-4CEB-920C-EECC3F5388A4Q35226451-B8AF9C6A-3BF8-445B-8A27-14FDFAB3A819Q35237236-04B443C1-BAC3-4CE7-9CD9-BB3F6EEDBAD6Q35575584-3534D0FF-A21F-407B-BD21-53C0E351A1F1Q35679776-ABCA7F51-08DC-480C-AAE2-6AD6841FEE97Q35791989-6059F198-C979-47E5-B809-FADF6DA8933AQ35854145-1143ACB1-9861-4DF8-BFB7-D95EEB731224Q36136786-93F34348-4E07-4B6E-97D2-7FD0C9C74F40Q36398661-CC01F329-0A28-4245-8D32-3FCAB415CFC1Q36499868-48C824F7-22B0-410B-9184-8CDB7AC767C1Q36570194-3481A8D3-DD1B-4FA0-BB4C-04AB8B98980CQ36702588-FBB18CE3-FD89-4B9D-8D2A-4A44AE26E07DQ36943676-F91385FF-6AAD-401E-AC7C-41DDB2498770Q37277889-9D657803-4185-4C9A-8BD2-E94B51ECC773Q37292136-2128E403-1128-43D4-BEBF-5C16D978FBE1Q37328458-E554B898-9368-4B1A-BBDF-F5DF2DE64A91Q37328913-885781F1-CC47-4D76-BA0F-3E7019BBFF0EQ37353680-37964B51-5C5B-4B0F-A5EB-D75E03669AFCQ37532496-7B4BE3F2-7C2C-4E5F-A580-FEADAA49EC7FQ37538787-94757EDB-BD20-42BE-891B-F4E613CE26DEQ37612442-77947A98-E450-4ABC-A3A6-22AB8A5593FDQ37684710-B466555A-FF40-4A72-90FC-3A18F2913227Q37790364-4BF01F1A-0E14-4846-9FC0-B3D15D413782Q37867481-D50AFDD9-557C-497E-A740-CCFD96AABFB0Q37898706-517BA953-F3DE-4570-B3D5-5705393AD0B0Q38121519-2DB6F754-B576-4CF8-8543-BF66B46A54C3Q38127586-7FC2D2A7-EF5D-4418-9D06-068CCA53E4B3
P2860
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recommendations from the EGAPP ...... serotonin reuptake inhibitors.
@en
Recommendations from the EGAPP ...... serotonin reuptake inhibitors.
@nl
type
label
Recommendations from the EGAPP ...... serotonin reuptake inhibitors.
@en
Recommendations from the EGAPP ...... serotonin reuptake inhibitors.
@nl
prefLabel
Recommendations from the EGAPP ...... serotonin reuptake inhibitors.
@en
Recommendations from the EGAPP ...... serotonin reuptake inhibitors.
@nl
P2860
P1433
P1476
Recommendations from the EGAPP ...... serotonin reuptake inhibitors.
@en
P2093
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
P2860
P2888
P304
P356
10.1097/GIM.0B013E31815BF9A3
P407
P577
2007-12-01T00:00:00Z
P6179
1044359340